Docosahexaenoic acid (DHA) in infant formula at concentrations based on worldwide human milk has resulted in circulating red blood cell (RBC) lipids related to visual and cognitive development. In this study, infants received study formula (17 mg DHA/100 kcal) with a commercially-available (Control: n=140; DHASCO®) or alternative (DHASCO®-B: n=127) DHA single cell oil from 14 to 120 days of age. No significant group differences were detected for growth rates by gender through 120 days of age. Blood fatty acids at 120 days of age were assessed by capillary column gas chromatography in a participant subset (Control: n=34; DHASCO-B: n=27). The 90% confidence interval (91-104%) for the group mean (geometric) total RBC DHA (µg/mL) ratio fell within the pre-specified equivalence limit (80-125%), establishing study formula equivalence with respect to DHA. This study demonstrated infant formula with DHASCO-B was safe, well-tolerated, and associated with normal growth. Furthermore, DHASCO and DHASCO-B represented equivalent sources of DHA as measured by circulating RBC DHA.
Introduction
Human milk, the standard for infant feeding and nutrition, provides the long chain polyunsaturated fatty acid (LCPUFA) docosahexaenoic acid (DHA; 22:6n-3). DHA is present in high concentrations in brain grey matter and photoreceptor cell membranes of the retina and accumulates in the central nervous system during the third trimester in utero and through two years of age [1] . Total red blood cell (RBC) and plasma phospholipid (PPL) fatty acid composition have been commonly used as outcomes in studies of infant formulas with added algal-derived preformed DHA single cell oil (DHASCO®) [2, 3] based on worldwide human milk composition (~0.3% of total fatty acids) [4, 5] and associated with RBC LCPUFAs comparable to those of breastfed infants [2, 3, 6] , visual and cognitive development in term infants [2, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] , and enhanced growth and neural development in preterm infants [17, 18] . DHASCO is derived from the marine microalgae Crypthecodinium cohnii; has a history of safe use as the main DHA source in routine, premature, and other specialty infant formulas (such as soy and hydrolyzed protein) [2, 3, [7] [8] [9] [10] [11] [17] [18] [19] [20] ; and has been generally recognized as safe (GRAS) by the US Food and Drug Administration (FDA) for use in infant formulas since 2001 [21, 22] .
DHA is currently considered either an optional or mandatory ingredient for infant formula. As new ingredients appropriate for use in infant formulas are developed and become commercially available safety and suitability must be assessed, including sources of DHA. DHASCO®-B is a new single cell oil derived from another common marine algae Schizochytrium sp., developed in accordance with Good Manufacturing Practices, and may be used as a replacement for DHASCO [23] . Both DHASCO and DHASCO-B are sources of DHA (minimum of 40% of total fatty acids), the 22 carbon fatty acid with 6 unconjugated double bonds-the first of which is located at the third carbon from the methyl end, with fatty acids predominantly esterified as triacylglycerols, similar to human milk [24] . DHASCO-B is GRAS for use in preterm and term, exempt and non-exempt infant formulas and follow-on formulas [25] and is approved as a Novel Food by Health Canada as a source of DHA for use in infant formula, follow-on infant formula, and foods for special dietary use for children under 3 years of age [26] . In addition, oil from the micro-algae Schizochytrium sp. has been authorized for use in infant and follow-on formula by the European Commission [27] , when used in accordance with the European regulatory standard on infant formulae and follow-on formulae [28] . Safety data is available from rodent genotoxicity and neonatal piglet studies [29, 30] , the latter considered the most appropriate model to safely examine new constituents of infant formula [31] . To evaluate nutritional bioequivalence and safety, DHASCO-B or DHASCO (each used in a blend with arachidonic acid [ARA] single cell oil [ARASCO®] in a milk replacer formula) were provided to preweaning piglets over a 3-week postnatal feeding period; both were well tolerated with no differences observed in tissue DHA accretion (heart, liver and brain) or circulating RBC and plasma DHA [30] .
In the present study, we evaluated the effect of an investigational routine intact protein cow's milk-based ready-to-use (RTU) liquid formula with DHASCO-B as the source of DHA (17 mg/100 kcal), ARASCO as the source of ARA (34 mg/100 kcal) and a prebiotic blend of polydextrose (PDX) and galactooligosaccharides (GOS) (1:1 ratio, 4 g/L) on growth and tolerance in healthy term infants. Rate of weight gain (g/day) from 14 to 120 days of age was evaluated as the primary variable to establish that the investigational study formula with DHASCO-B provided adequate growth compared to the marketed Control formula with DHASCO. In a subset of study participants, a secondary objective was to compare group RBC DHA concentrations (μg/mL) to establish the equivalence with respect to DHA for study formulas.
Methods

Study population
Healthy 10-to 14-day old infants were recruited at 21 clinical sites in the United States. Eligible infants were singleton births at 37-42 weeks gestational age with birth weight ≥2500 g and solely formula-fed at least 24 h prior to randomization. Exclusion criteria included history of underlying disease or congenital malformation likely to interfere with normal growth and development or participant evaluation; feeding difficulties or history of formula intolerance; weight at randomization < 98% of birth weight; large for gestational age (as confirmed from hospital birth records) from mother who was diabetic at childbirth; and immunodeficiency.
Study design
In this multicenter, double-blind, randomized, controlled, parallelgroup, prospective trial, participants were enrolled between May and November 2014. Parents or legally authorized representative provided written informed consent prior to enrollment. The research protocol and informed consent forms observing the Declaration of Helsinki (including October 1996 amendment) were approved by the institutional review board/ethics committee of each participating institution. The study complied with Good Clinical Practices. The study sponsor created a computer-generated, gender-stratified randomization schedule provided in sealed consecutively-numbered envelopes for each study site. Study formula was assigned by opening the next sequential envelope from the appropriate set at the study site. Study formulas were each designated by two unique codes known only to the sponsor and dispensed to parents at each study visit prior to completion or withdrawal. Neither the product labels nor the sealed envelopes allowed direct unblinding by the study site. Personnel responsible for monitoring the study were also blinded to study product identification.
Blinding for a participant could be broken by study sponsor personnel in the event of a medical emergency in which knowledge of the study formula was critical to the participant's management. In this study, it was not necessary to break the study code prematurely.
Participants were randomly assigned to receive a routine cow's milk-based infant formula (Control; marketed Enfamil®, Mead Johnson Nutrition, Evansville, IN) with the current DHA source (DHASCO; 17 mg/100 kcal) or an investigational cow's milk-based formula with an alternative DHA source (DHASCO-B; 17 mg/100 kcal) from 14 to 120 days of age (Table 1) . DHASCO-B is a new single cell oil with DHA as the predominant fatty acid constituent (~40% of total fatty acids). The GRAS notice for DHASCO-B from the manufacturer (DSM Nutritional Products, Columbia, MD) provides detailed specifications; briefly, other major fatty acids ( > 1% of total fatty acids) include myristic acid (~1%); palmitic acid (~13-14%); stearic acid (~1.5%); oleic acid (~25%); docosapentaenoic acid (DPAn-6;~3%); and eicosapentaenoic acid (EPA;~6%, maximum 10%) as well as comprehensive information regarding the characterization of the marine algae Schizochytrium sp., method of DHASCO-B manufacture and extraction, and toxicology reporting to support safety of use [23] . Study formulas were provided as ready-to-use (RTU) liquids (20 cal/ fluid ounce) with ARASCO as the source of ARA (34 mg/100 kcal) and a prebiotic blend of PDX (Litesse ® Two Polydextrose; Danisco) and
For formulas in the current study, fatty acid composition was representative of previously studied formulas with DHASCO formu- lated to contain 17 mg DHA/100 kcal [2, 7, 11, 13] . Study formula fatty acid composition as a percent of total fatty acids (wt/wt) is presented as supplemental information (Supplemental Table 1 ). Nutrients in infant formulas, including DHA, are formulated to meet expert recommendations and regulatory requirements, as well as mitigate analytical and manufacturing variability, and provide integrity over shelf life. Quality control and Good Manufacturing Practices ensure target nutrient values remain within a narrow range.
Study objectives and outcomes
Growth and tolerance
The objective was to evaluate growth and tolerance in healthy, term infants. Anthropometric measures (body weight, length, and head circumference) were recorded at study visits corresponding to 14, 30, 42, 60, 90, and 120 days of age. Parents completed a 24-hour recall of tolerance (fussiness and gassiness) and stool characteristics (frequency and consistency) at all study visits and study formula intake (fluid oz/ day) beginning at the 30 days of age visit. Responses were scaled for amount of gas (none, slight amount, moderate amount, excessive amount); fussiness (not fussy, slightly fussy, moderately fussy, very fussy, extremely fussy); and stool consistency (hard, formed, soft, unformed or seedy, watery). Adverse events were coded according to specific event (e.g. otitis media, colic, etc.) and the body system involved including: Body as a Whole; Cardiovascular; Endocrine; Eye, Ears, Nose, and Throat; Gastrointestinal; Metabolic and Nutrition; Musculoskeletal; Nervous; Respiratory; Skin; and Urogenital.
Fatty acid analysis
At five investigative sites experienced in handling clinical blood samples and with appropriate storage facilities, blood samples at 120 days of age were collected by venipuncture into EDTA Vacutainer tubes. For fatty acid analysis, plasma and RBC were separated by centrifugation and frozen. Samples were shipped on dry ice to the Retina Foundation of the Southwest (Dallas, TX) where lipids were extracted, fractionated by thin-layer chromatography (plasma phospholipids [PPLs] only), and analyzed by capillary column gas chromatography as previously described [2] . Fatty acid methyl esters from RBC lipids and the PPL fraction were reported as concentrations (μg/ mL) and as a percent of total fatty acids (wt/wt).
Statistical methods
The primary outcome was weight growth rate from 14 to 120 days of age. The sample size was chosen to detect a clinically relevant difference of 3 g/day in weight gain from 14 to 120 days of age (80% power). Assuming a standard deviation of 6.5 g/day for male and 5.5 g/ day for female participants, approximately 91 males and 66 females were needed to enroll in each group with the expectation that 59 male and 43 female participants per study group would complete the study. Analysis of variance (ANOVA) was used to assess growth rates from 14 to 30, 42, 60, 90, or 120 days of age calculated for each participant by linear regression of weight on age. Mean weight growth rates by gender for the investigational formula group was compared with the control using a one-tailed test as outlined in guidance provided by the American Academy of Pediatrics (AAP) Task Force on Clinical Testing of Infant Formulas [32] .
Secondary outcomes included blood lipids, other anthropometric and tolerance measures, and medically-confirmed adverse events. Per the United States FDA guidance for bioequivalence studies [33] , a prespecified equivalence range (0.80-1.25) for total RBC DHA concentration at 120 days of age was used to establish the bioequivalence of the two study formulas with respect to DHA. Assuming a coefficient of variation of 0.2 (95% power), a subset of approximately 22 participants per formula group were required to complete the study and have a blood sample drawn at 120 days of age. The natural logs of the total RBC DHA concentration data were analyzed by ANOVA with a term for study group included. A 90% confidence interval (CI) for the difference in the total RBC DHA means (DHASCO-B minus Control) was calculated. The antilogs of the confidence limits obtained formed a 90% CI for the ratio of the geometric means between the investigational (DHASCO-B) and Control formulas. If the resulting CI fell within the pre-specified equivalence range (0.80-1.25), then equivalence with respect to DHA was established.
Achieved weight, length, and head circumference; length and head circumference growth rates; formula intake; stool frequency; and total RBC and plasma phospholipid (PPL) fatty acid data were analyzed by ANOVA. Stool consistency, fussiness, and gas were analyzed using the Cochran-Mantel-Haenszel (CMH) row means score test. Incidence of adverse events was analyzed using Fisher's exact test. With the exception of p-values reported from the analysis of weight gain based on one-tailed tests, all other p-values reported were based on two-tailed tests. All testing was conducted at α=0.05. All analyses were conducted using SAS version 9.2 (Cary, NC).
Results
Participants
A total of 360 participants were enrolled and randomized (Control: n=184; DHASCO-B: n=176). Participants who were randomized but consumed no study formula (Control: n=2; DHASCO-B: n=4) were not included in subsequent analyses (Fig. 1) . No differences in body weight, length, or head circumference were observed by gender between groups at study enrollment (Table 2 ). Birth anthropometric measures as well as gender, race, and ethnic distribution were also similar between groups (data not shown). No statistically significant group differences were detected for study discontinuation (Control: n=42, 23%; DHASCO-B: n=45, 26%) or discontinuation related to study formula (Control: n=19, 10%; DHASCO-B: n=11, 6%). In the total study population, 27 participants (8%) discontinued due to formula intolerance as determined by the study investigator with gas (Control: n=11; DHASCO-B: n=3) and fussiness (Control: n=9; DHASCO-B: n=5) as the most common indicators. Parental decision was the most common reason for discontinuation unrelated to study formula (42 participants, 12%). A total of 267 infants completed the study (Control: n=140; DHASCO-B: n=127).
Growth
Growth rates were analyzed from 14 to 120 days of age. No statistically significant group differences by gender in the primary outcome, weight growth rate from day 14-120, were detected (Table 3) . No statistically significant group differences by gender in weight, length, or head circumference growth rates were detected for any age range. In addition, no significant group differences were observed for mean achieved weight, length, or head circumference at any measured time point. Finally, mean achieved weight plotted on the WHO weightfor-age standard growth chart [34, 35] tracked along the 50th percentile for males (Fig. 2) and remained between the 25th and 50th percentiles for females (Fig. 3 ) at all measured time points.
Tolerance
No group differences in parent-reported gassiness and fussiness or stool characteristics were detected at any time point assessed (data not shown). The amount of gas most commonly reported was "slight" or "moderate" and fussiness was most often characterized as "slightly fussy" in both groups. For stool consistency the majority of participants in both groups from enrollment to day 120 were reported to have a "soft" or "unformed or seedy" stool consistency. No group differences in parent-reported study formula intake by gender were detected any time point assessed (data not shown). In addition, mean reported intakes increased from day 30 to 120 for both groups by gender, indicating normal intake for this time period. No group difference was detected in the number of participants for whom at least one medically-confirmed adverse event was reported (Control: n=135, 74%; DHASCO-B: n=121, 70%; P=0.476). The incidence of adverse events categorized within Body as a Whole; Cardiovascular; Endocrine; Eyes, Ears, Nose, and Throat; Metabolic and Nutrition; Musculoskeletal; Nervous System; Skin; or Urogenital systems were generally low with no statistically significant group differences for specific events. In the Gastrointestinal (GI) and Respiratory Systems no significant group differences for specific adverse events were detected; gastroesophageal reflux (Control: n=24, 13%; DHASCO-B: n=35, 20%) and upper respiratory infection (Control: n=37, 20%; DHASCO-B: n=28, 16%) were the most commonly reported specific adverse events by category. Any medicallyconfirmed adverse event was considered serious if it met one or more of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or was a congenital anomaly/birth defect. A total of 9 participants experienced serious adverse events (Control: n=5, 3%; DHASCO-B: n=4, 2%). All serious adverse events were individually evaluated by study site physicians and each was determined unrelated to study formulas.
Blood lipids
Total RBC and PPL fatty acids (mean ± SE) as concentrations (μg/ mL) ( Table 4 ) and percent of total fatty acids (wt/wt) ( Table 5 ) from blood lipid fractions at 120 days of age were evaluated. No group differences in RBC total or individual saturated and monounsaturated fatty acid concentrations or as a percent of total fatty acids were detected. With the exception of significantly lower PPL lignoceric acid (24:0), oleic acid (18:1), and total monounsaturated fatty acids as a percent of total fatty acids in the Control compared to the DHASCO-B group, no other group differences in PPL saturated and monounsaturated fatty acids were detected (concentration and percent of total fatty acids). No statistically significant group differences were detected in RBC or PPL total n-3 or n-6 PUFAs (concentration and percent of total fatty acids). With the exception of significantly lower RBC and PPL EPA (20:5n-3), DPAn-3 (22:5n-3), and DPAn-6 (22:5n-6) for the Control compared to DHASCO-B group, no other group differences in individual RBC or PPL n-3 or n-6 PUFAs were detected (concentration and percent of total fatty acids). In particular, no group differences in RBC or PPL DHA (22:6n-3) or ARA (20:4n-6) were detected.
DHA equivalence
The calculated 90% CI for the ratio of the mean (geometric) DHA concentration (µg/mL) in total RBCs for participants receiving the investigational compared to the Control formula needed to fall within an equivalence limit of 80-125% in order to conclude the equivalence Did not consume study formula males, n = 0 females, n = 2
Did not consume study formula males, n = 3 females, n = 1 Discontinued Formula-related males, n = 5 females, n = 6 Not formula-related males, n = 22 females, n = 12 Discontinued Formula-related males, n = 11 females, n = 9 Not formula-related males, n = 10 females, n = 12 with respect to DHA. For total RBC DHA, confidence interval for the investigational relative to the Control group was 91-104%.
Discussion
This study demonstrated that an investigational routine intact protein cow's milk-based ready-to-use (RTU) liquid formula with DHASCO-B (source of DHA, 17 mg/100 kcal), ARASCO (source of ARA, 34 mg/100 kcal) and a prebiotic blend (PDX and GOS; 1:1 ratio, 4 g/L) was safe and well-tolerated when fed to healthy term infants from 14 to 120 days of age. The investigational formula was also associated with normal growth throughout the study. As outlined in guidance provided by the AAP Task Force on Clinical Testing of Infant Formulas, rate of weight gain (g/day) is used as the most important parameter in clinical evaluation of nutritional suitability of infant formulas [32] . No statistically significant group differences were observed for weight, length, or head circumference growth rates from 14 to 120 days of age. Mean achieved weight for males and females were within the 25th and 75th percentiles of the WHO weight-for-age growth chart from 14 to 120 days of age and no group differences for mean achieved weight, length, or head circumference by gender were detected at any measured time point. Calculated confidence intervals of DHA concentrations in total RBC fell within the pre-specified equivalence limit of 80-125%, thus establishing equivalence of study formulas with respect to DHA.
Postnatal diet, in combination with LCPUFA status at birth-in itself a function of maternal fatty acid status and reflective of maternal diet and genetic polymorphisms-influences postnatal changes in infant blood LCPUFA status across populations [36, 37] . DHA incorporation into RBCs is a practical surrogate for measuring DHA accumulation into the brain [2, 38] because DHA in RBC and neural membranes exhibit a relative response to dietary modification [39] . Previous studies with formula with DHASCO as the source of DHA have demonstrated significant positive correlations between RBC DHA and improved cognitive and visual outcomes [2, 7, 8, [11] [12] [13] [14] [15] [16] . Results of the current study in healthy infants from 14 to 120 days of age demonstrated routine infant formulas with DHASCO or DHASCO-B as the source of DHA were associated with equivalent concentrations of circulating total RBC DHA. In addition, group RBC DHA mean concentrations in the current study at 120 days of age (Control: 90.2 µg/mL; DHASCO-B: 88.1 µg/mL) were within the previously reported range (77-113 µg/mL) for infants receiving infant formula with DHASCO as the source of DHA (formulated at 17 mg/100 kcal) up to 120 days of age [2, 7, 11, 13] . Similarly, group RBC ARA mean concentrations in the current study at 120 days of age (Control: 243.6 µg/mL; DHASCO-B: 240.8 µg/mL) were within the previously reported range (178-268 µg/mL) for infants receiving formula with ARASCO as the source ARA (formulated at 34 mg/100 kcal) up to 120 days of age [2, 7, 11, 40] . Consequently, infant formula with DHASCO-B (as a source of DHA) produces RBC DHA within the range representative of the totality of previous clinical data and comparable to previous clinical studies with infants receiving formula with DHASCO (as an equivalent source of DHA). The current data therefore suggests the availability of circulating DHA for central nervous system development and function in infants. Recently-consumed fatty acids generally comprise a greater proportion of PPL compared to RBC composition in the postprandial period [41] . In the current study blood was collected in the unfasted state, thus RBC would be influenced to a lesser extent by recent dietary intake than PPL and therefore considered a more definitive marker of fatty acid content for other body tissues. Consequently, the few differences detected in PPL saturated and monounsaturated fatty acids were not considered clinically relevant. No statistically significant group differences were detected in RBC or PPL total n-3 or n-6 PUFAs. With the exception of lower RBC and PPL EPA (20:5n-3), DPAn-3 (22:5n-3), and DPAn-6 (22:5n-6) for the Control compared to DHASCO-B group, no other group differences in RBC or PPL individual n-3 or n-6 PUFAs were detected. Unlike DHASCO, as previously noted, DHASCO-B is also a source of some EPA (~6%) and DPAn-6 (~3% of total fatty acids) [23] , which are fatty acids also present in human milk [24] . These distinctions in single cell oil fatty acid composition would be less pronounced in the final study formula composition (each < 0.1% of total fatty acids, as estimated) but potentially still reflective of very minor group differences observed in circulating EPA and DPAn-6. In both DHASCO and DHASCO-B, DPAn-3 is present in extremely low quantities ( < 1% of total fatty acids) [23] . However, endogenous synthesis of DPAn-3 from EPA may occur and could potentially contribute to blood fatty acid concentrations [42, 43] . Global infant formula standards (such as CODEX Alimentarius and those in the European Union, China, and Australia) that regulate DHA as an optional ingredient [44] [45] [46] [47] or compositional requirement [28] recognize EPA can be present in sources of LCPUFA and that the content of EPA in formula for infants should not exceed the content of DHA. In line with meeting these regulations, EPA is lower than DHA in DHASCO-B (~6% compared to~44% of total fatty acids). In the current study, EPA, DPAn-3, and DPAn-6 were relatively minor constituents of blood samples (each < 1% of total fatty acids). Consequently, the differences detected in these blood fatty acids did not affect formula safety and tolerance outcomes or association with normal infant growth and therefore not considered clinically relevant. Despite small differences in blood fatty acid composition, both DHASCO and DHASCO-B represent equally bioavailable sources of DHA.
Overall, acceptance and tolerance of study formulas were good. No differences in study discontinuation due to study formula were detected. No significant group differences were detected in fussiness or gassiness and stool frequency or consistency. Stool consistency was in the soft or seedy range for both groups at all measured time points. The current results are consistent with our previous reports in which use of routine formulas that have PDX and GOS (4 g/L; 1:1 ratio) was well tolerated, safe, promoted normal growth and produced softer stools in healthy, term infants [48, 49] and produced a bifidogenic effect closer to human milk [50] compared to infants receiving formulas with no PDX and GOS.
Conclusion
In the current study in healthy, term infants receiving a routine intact protein cow's milk-based formula with DHASCO-B as the source of DHA (17 mg/100 kcal), ARASCO as the source of ARA (34 mg/ 100 kcal), and a prebiotic blend (PDX and GOS; 1:1 ratio, 4 g/L) was well-tolerated and supported normal growth. In addition, calculated confidence intervals of DHA concentrations in total RBC fell within the pre-specified equivalence limit of 80-125%, suggesting that routine infant formula with the existing or alternative source of DHA were associated with equivalent concentrations of circulating total RBC DHA. 
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